Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
UNLABELLED: The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and liraglutide, suppress food intake and body weight. The mediating site(s) of action for the anorectic effects produced by peripheral administration of these GLP-1R agonists are not known. Experiments addressed whether food intake suppression after i.p. delivery of exendin-4 and liraglutide is mediated exclusively by peripheral GLP-1R or also involves direct central nervous system (CNS) GLP-1R activation. Results showed that CNS delivery [third intracerebroventricular (3(rd) ICV)] of the GLP-1R antagonist exendin-(9-39) (100 μg), attenuated the intake suppression by i.p. liraglutide (10 μg) and exendin-4 (3 μg), particularly at 6 h and 24 h. Control experiments show that these findings appear to be based neither on the GLP-1R antagonist acting as a nonspecific competing orexigenic signal nor on blockade of peripheral GLP-1R via efflux of exendin-(9-39) to the periphery. To assess the contribution of GLP-1R expressed on subdiaphragmatic vagal afferents to the anorectic effects of liraglutide and exendin-4, food intake was compared in rats with complete subdiaphragmatic vagal deafferentation and surgical controls after i.p. delivery of the agonists. Both liraglutide and exendin-4 suppressed food intake at 3 h, 6 h, and 24 h for controls; for subdiaphragmatic vagal deafferentation rats higher doses of the GLP-1R agonists were needed for significant food intake suppression, which was observed at 6 h and 24 h after liraglutide and at 24 h after exendin-4. CONCLUSION: Food intake suppression after peripheral administration of exendin-4 and liraglutide is mediated by activation of GLP-1R expressed on vagal afferents as well as direct CNS GLP-1R activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is consistent with some prior studies demonstrating a role for NTS GLP-1R neurons in physiological satiation/satiety and for some of the anorectic effects of various GLP-1RAs, with some reporting an absence of evidence of proxies for nausea (109‐113).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [110]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“The long-acting GLP-1R agonists, exendin-4 and liraglutide, are efficacious in the treatment of T2DM and may hold promise for the treatment of obesity (5, 6, 28).”
BackgroundOgden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Abbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599 · cited 1×
“Similarly, others also show that ip administration of GLP-1 does not suppress short-term intake after total subdiaphragmatic vagotomy (12), and ip exendin-4 does not suppress intake up to 8 h after administration in capsaicintreated mice (50).”
BackgroundAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Göke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Glucoreceptors Controlling Feeding and Blood Glucose: Location in the Hindbrain
Ritter, R. C., Slusser, P. G., & Stone, S. (1981) · Science · doi:10.1126/science.6264602 · Cited by 467 · cited 1×
“After a 7-d surgical recovery period, 3 ICV cannula placement was assessed by measurement of the sympathoadrenal-mediated hyperglycemic response to the cytoglucopenia induced by 5-thio-D-glucose (210 g in 2 l aCSF) (20).”
MethodGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416
Afferent axons in abdominal vagus mediate satiety effect of cholecystokinin in rats
Smith, G. P., Jerome, C., & Norgren, R. (1985) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1985.249.5.r638 · Cited by 372
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355 · cited 1×
“This, coupled with evidence that exendin-4 (17) and liraglutide (18) penetrate the BBB in rats potentially via passive diffusion, suggests that the energy balance effects of peripheral administration of these GLP-1R agonists may result, in part, from direct activation of GLP-1R expressed in CNS nuclei critical to ener…”
BackgroundTalsania, T., Anini, Y., Siu, S., Drucker, D. J., & Brubaker, P. L. (2005) · Endocrinology · doi:10.1210/en.2005-0473 · Cited by 306 · cited 2×
“Similarly, others also show that ip administration of GLP-1 does not suppress short-term intake after total subdiaphragmatic vagotomy (12), and ip exendin-4 does not suppress intake up to 8 h after administration in capsaicintreated mice (50).”
BackgroundResultEvidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · cited 3×
“(14) show that ICV administration of the GLP-1R antagonist exendin-(9–39) fails to attenuate 30-min intake suppression by ip GLP-1(7–36).”
BackgroundKinzig, K. P., D'Alessio, D. A., & Seeley, R. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-23-10470.2002 · Cited by 296 · cited 2×
“Also, given that regionally distinct CNS GLP-1R populations have been implicated in food intake control and visceral illness (39), it is unclear whether the attenuation of intake suppression observed with ICV exendin-(9–39) cotreatment is based on amelioration of the satiating, nauseating, or combined effects of the G…”
BackgroundGlucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors
Holst, J. J., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1705-7 · Cited by 288 · cited 4×
“Significant main effects of sCT were obtained at 3 h and 6 h [Fs(1,7) 14.”
BackgroundInfluentialExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265 · cited 2×
“To determine whether ICV exendin-(9–39) acts as a nonspecific competing orexigenic signal through blockade of basal CNS GLP-1R signaling (25, 26), we examined whether ICV exendin(9–39) could attenuate the intake suppression by a non-GLP-1 peripherally administered anorectic agent, the amylin receptor agonist, sCT.”
BackgroundRüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2009) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 258 · cited 4×
“Further, ip administration of low doses of GLP-1, resembling the physiological profile of action for endogenous GLP-1 released from intestinal L cells, reduces food intake in sham-operated rats, but not in rats with subdiaphragmatic vagal deafferentation (SDA) (13).”
BackgroundMethodResultInfluentialSelf-citationVagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin
Moran, T. H., Baldessarini, A. R., Salorio, C. F., Lowery, T., & Schwartz, G. J. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.272.4.r1245 · Cited by 236
Arnold, M., Mura, A., Langhans, W., & Geary, N. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2606-06.2006 · Cited by 233 · cited 3×
“Using an inclusion criteria used by others, SDA rats were included in the statistical analyses if CCK treatment resulted in a less than 30% reduction of their food intake (13, 21).”
MethodResultSelf-citationHayes, M. R., Bradley, L., & Grill, H. J. (2009) · Endocrinology · doi:10.1210/en.2008-1479 · Cited by 228 · cited 1×
“GLP-1R-mediated control of food intake (36).”
Self-citationHayes, M. R., Skibicka, K. P., & Grill, H. J. (2008) · Endocrinology · doi:10.1210/en.2007-1743 · Cited by 214
Self-citationRaun, K., von Voss, P., Gotfredsen, C. F., Golozoubova, V., Rolin, B., & Knudsen, L. B. (2007) · Diabetes · doi:10.2337/db06-0565 · Cited by 207
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Abu-Hamdah, R., Rabiee, A., Meneilly, G. S., Shannon, R. P., Andersen, D. K., & Elahi, D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1296 · Cited by 200
McMahon, L. R., & Wellman, P. J. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.1.r23 · Cited by 199
Distributed Neural Control of Energy Balance: Contributions from Hindbrain and Hypothalamus
Grill, H. J. (2006) · Obesity · doi:10.1038/oby.2006.312 · Cited by 191
Self-citationRole of the glucagon-like-peptide-1 receptor in the control of energy balance
Hayes, M. R., De Jonghe, B. C., & Kanoski, S. E. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.02.029 · Cited by 173 · cited 1×
“The long-acting GLP-1R agonists, exendin-4 and liraglutide, are efficacious in the treatment of T2DM and may hold promise for the treatment of obesity (5, 6, 28).”
BackgroundSelf-citationVrang, N., Hansen, M. B., Larsen, P. J., & Tang‐Christensen, M. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.043 · Cited by 163
Mojsov, S., Kopczynski, M. G., & Habener, J. F. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39030-1 · Cited by 159 · cited 1×
“entry into the gastrointestinal (GI) tract (4) and acts on”
BackgroundBrain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) after Intranasal Administration
Banks, W. A., During, M. J., & Niehoff, M. L. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.063222 · Cited by 155 · cited 2×
“Although the exact percent of exendin-(9–39) efflux from the CNS in experiment 1a cannot be determined, previous work estimates the amount of exendin-(9–39) found in peripheral circulation after central administration in mice is approximately 17% (27).”
BackgroundMadsen, A. N., Hansen, G., Paulsen, S. J., Lykkegaard, K., Tang-Christensen, M., Hansen, H. S., Levin, B. E., Larsen, P. J., Knudsen, L. B., Fosgerau, K., et al. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0004 · Cited by 152
Receptor‐mediated activation of gastric vagal afferents by glucagon‐like peptide‐1 in the rat
Bucinskaite, V., Tolessa, T., Pedersen, J., Rydqvist, B., Zerihun, L., Holst, J. J., & Hellström, P. M. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01317.x · Cited by 135
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00870.2004 · Cited by 128
The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size
Scott, K. A., & Moran, T. H. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00323.2007 · Cited by 113
Liraglutide: the therapeutic promise from animal models
Knudsen, L. B. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02499.x · Cited by 99 · cited 1×
“The long-acting GLP-1R agonists, exendin-4 and liraglutide, are efficacious in the treatment of T2DM and may hold promise for the treatment of obesity (5, 6, 28).”
BackgroundBecskei, C., Grabler, V., Edwards, G. L., Riediger, T., & Lutz, T. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.06.016 · Cited by 98
Raun, K., von Voss, P., & Knudsen, L. B. (2007) · Obesity · doi:10.1038/oby.2007.204 · Cited by 93 · cited 3×
“05]; however, the Group Drug interactions did not achieve significance at 6 h and 24 h [Fs(2,32) 1.”
BackgroundA method for selective section of vagal afferent or efferent axons in the rat
Norgren, R., & Smith, G. P. (1994) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1994.267.4.r1136 · Cited by 90 · cited 1×
“In another experiment the contribution of GLP-1R expressed on subdiaphragmatic vagal afferents was examined by comparing responses from rats with complete SDA (19) to sham-operated controls after ip administration of exendin-4 and liraglutide.”
MethodTurning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors
Grady, E. F., Bohm, S. K., & Bunnett, N. W. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.3.g586 · Cited by 87
Suppression of meal size by intestinal nutrients is eliminated by celiac vagal deafferentation
Walls, E. K., Phillips, R. J., Wang, F. B., Holst, M. C., & Powley, T. L. (1995) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1995.269.6.r1410 · Cited by 84
Schepp, W., Schmidtler, J., Riedel, T., Dehne, K., SCHUSDZIARRA, V., Holst, J. J., Eng, J., Raufman, J., & Classen, M. (1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90085-x · Cited by 66
Bradley, D. P., Kulstad, R., & Schoeller, D. A. (2010) · Nutrition · doi:10.1016/j.nut.2009.07.008 · Cited by 64
Baumgartner, I., Pacheco‐López, G., Rüttimann, E. B., Arnold, M., Asarian, L., Langhans, W., Geary, N., & Hillebrand, J. J. G. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.01995.x · Cited by 64
Self-citationMcMahon, L. R., & Wellman, P. J. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)90017-4 · Cited by 53
Hayes, M. R., & Covașă, M. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.018 · Cited by 46
Self-citationBaraboi, E.-D., Smith, P., Ferguson, A. V., & Richard, D. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00326.2009 · Cited by 46 · cited 2×
“Statistical support for these conclusions was provided by a significant Group Drug interaction [F(3,48) 5.”
BackgroundMethodReidelberger, R. D., Haver, A. C., Apenteng, B. A., Anders, K. L., & Steenson, S. M. (2011) · Obesity · doi:10.1038/oby.2010.136 · Cited by 43
An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice
Morley, J. E., & Flood, J. F. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90534-0 · Cited by 42
Viltart, O., Sartor, D. M., & Verberne, A. J. M. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.07.016 · Cited by 35
Liraglutide for weight loss in obese people
Thum, T., & Anker, S. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60226-7 · Cited by 12
Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationAlhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515
Self-citationGLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Hindbrain Neurons as an Essential Hub in the Neuroanatomically Distributed Control of Energy Balance
Grill, H. J., & Hayes, M. R. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.015 · Cited by 485
“At the same time, recent experiments show that the central nervous system (CNS) action of energy status signals such as leptin, ghrelin, glucagon-like peptide-1 (GLP-1), and peptide YY (PYY) affect food preference, the incentive value of food, and other cognitive controls of food intake (Batterham et al., 2007; Kanosk…”
BackgroundInfluentialSelf-citationNeuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397
“We and others have shown previously that CNS pharmacological blockade of the GLP1R increases food intake (19, 26) and that central GLP1Rs are important in the anorectic effects of peripheral liraglutide (5).”
Metadata
- Authors
- Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R.
- Affiliations
- University of Pennsylvania (US)
- ETH Zurich (CH)
- Corresponding author
- Kanoski, Scott E.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2011-06-21
- Volume
- 152
- Issue
- 8
- Pages
- 3103-3112
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC3138234
- OpenAlex
- W1965072462
- Cited by
- 347
- References
- 51
- Citations by year
- 2026: 16 · 2025: 26 · 2024: 21 · 2023: 16 · 2022: 18 · 2021: 30 · 2020: 23 · 2019: 26 · 2018: 19 · 2017: 21 · 2016: 27 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 23
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (DK21397, DK089752)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK089752, DK085435, R01DK021397, F32DK089752, K01DK085435, DK 21397, R56DK021397)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, liraglutide, exendin-4, exendin-9-39, feeding inhibition, anorectic effect, vagal afferents, intracerebroventricular administration, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Animals, Appetite Depressants, Body Weight, Brain, Calcitonin, Eating, Male, Peptide Fragments, Peptides, Vagus Nerve, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.